Dual antiplatelet therapy for secondary prevention of coronary artery disease

Sophie Degrauwe,1 Thomas Pilgrim,2 Adel Aminian,3 Stephane Noble,4 Pascal Meier,4 Juan F Iglesias1

ABSTRACT
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD) compared with aspirin monotherapy, but at the expense of an increased risk of major bleeding. Nevertheless, the optimal duration of DAPT for secondary prevention of CAD remains uncertain, owing to the conflicting results of several large randomised trials. Among patients with stable CAD undergoing PCI with drug-eluting stents (DES), shorter durations of DAPT (3–6 months) were shown non-inferior to 12 or 24 months duration with respect to MACE, but reduced the rates of major bleeding. Contrarily, prolonged DAPT durations (18–48 months) reduced the incidence of myocardial infarction and stent thrombosis, but at a cost of an increased risk of major bleeding and all-cause mortality. Until more evidence becomes available, the choice of optimal DAPT regimen and duration for patients with CAD requires a tailored approach based on the patient clinical presentation, baseline risk profile and management strategy. Future studies are however needed to identify patients who may derive benefit from shortened or extended DAPT courses for secondary prevention of CAD based on their individual ischaemic and bleeding risk. Based on limited evidence, 12 months duration of DAPT is currently recommended in patients with ACS irrespective of their management strategy, but large ongoing randomised trials are currently assessing the efficacy and safety of a short-term DAPT strategy (3–6 months) for patients with ACS undergoing PCI with newer generation DES. Finally, several ongoing, large-scale, randomised trials are challenging the current concept of DAPT by investigating P2Y12 receptor inhibitors as single antiplatelet therapy and may potentially shift the paradigm of antiplatelet therapy after PCI in the near future. This article provides a contemporary state-of-the-art review of the current evidence on DAPT for secondary prevention of patients with CAD and its future perspectives.

ANTIPLATELET AGENTS
Platelet inhibition plays a central role for treatment and prevention of short- and long-term atherothrombotic events in patients with CAD. Oral antiplatelet agents for secondary prevention of patients with CAD include the cyclo-oxygenase-1 inhibitor aspirin, and the platelet adenosine diphosphate P2Y12 receptor inhibitors clopidogrel, prasugrel and ticagrelor. Aspirin and clopidogrel have been studied across the whole spectrum of CAD, whereas the more recent potent P2Y12 platelet receptor inhibitors prasugrel and ticagrelor have been evaluated in patients with ACS. The main characteristics, mechanisms of action and indications of oral antiplatelet agents used for secondary prevention of CAD are summarised in table 1. Although there are several potential combinations of antiplatelet agents, DAPT refers to the therapy combining aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel or ticagrelor). DAPT has been shown to reduce recurrent major ischaemic events in patients...
## Table 1 Antiplatelet agents for secondary prevention of coronary artery disease

<table>
<thead>
<tr>
<th></th>
<th>Aspirin</th>
<th>Clopidogrel</th>
<th>Prasugrel</th>
<th>Ticagrelor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Molecule chemical class</strong></td>
<td>Acetylsalicylic acid</td>
<td>Thienopyridine</td>
<td>Thienopyridine</td>
<td>Cyclopentyl-triazolo-pyrimidined</td>
</tr>
<tr>
<td><strong>Route of administration</strong></td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Mechanism of action</strong></td>
<td>Cyclo-oxygenase-1 inhibition</td>
<td>P2Y12 receptor inhibition</td>
<td>P2Y12 receptor inhibition</td>
<td>P2Y12 receptor inhibition</td>
</tr>
<tr>
<td><strong>Loading dose</strong></td>
<td>150–300 mg (80–150 mg intravenously)</td>
<td>300–600 mg</td>
<td>60 mg</td>
<td>180 mg</td>
</tr>
<tr>
<td><strong>Maintenance dose</strong></td>
<td>75–150 daily</td>
<td>75 mg daily</td>
<td>10 (5) mg daily</td>
<td>90 mg twice daily</td>
</tr>
<tr>
<td><strong>Activation</strong></td>
<td>Prodrug, hydrolysis by an esterase</td>
<td>Prodrug, variable hepatic metabolism</td>
<td>Prodrug, predictable hepatic metabolism</td>
<td>Active drug with additional active metabolite</td>
</tr>
<tr>
<td><strong>Action</strong></td>
<td>Irreversible</td>
<td>Irreversible</td>
<td>Irreversible</td>
<td>Reversible</td>
</tr>
<tr>
<td><strong>Action onset</strong></td>
<td>30–40 min</td>
<td>2–6 hours</td>
<td>30 min</td>
<td>30 min</td>
</tr>
<tr>
<td><strong>Action duration</strong></td>
<td>5 days</td>
<td>3–10 days</td>
<td>7–10 days</td>
<td>3–5 days</td>
</tr>
<tr>
<td><strong>Interruption before surgery</strong></td>
<td>No interruption when possible (5 days if high bleeding risk surgery)</td>
<td>5 days</td>
<td>7 days</td>
<td>5 days</td>
</tr>
<tr>
<td><strong>Plasmatic half-life of prodrug</strong></td>
<td>2–3 hours</td>
<td>30–60 min</td>
<td>30–60 min</td>
<td>6–12 hours</td>
</tr>
<tr>
<td><strong>Inhibition of adenosine reuptake</strong></td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>► Stable CAD</td>
<td>► Stable CAD</td>
<td>► ACS scheduled for PCI</td>
<td>► ACS</td>
</tr>
<tr>
<td></td>
<td>► ACS</td>
<td></td>
<td>► Stable CAD after MI</td>
<td></td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>► Active bleeding</td>
<td>► Active bleeding</td>
<td>► Active bleeding</td>
<td>► Active bleeding</td>
</tr>
<tr>
<td></td>
<td>► Hypersensitivity to aspirin</td>
<td>► Severe hepatic failure</td>
<td>► History of stroke or TIA</td>
<td>► History of intracranial bleeding</td>
</tr>
<tr>
<td></td>
<td>► Severe hepatic failure</td>
<td></td>
<td>► Severe hepatic failure (Child-Pugh C)</td>
<td>► Moderate to severe hepatic failure</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>► Coadministration with potent cytochrome CYP3A4 inhibitors</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.
with ACS or undergoing PCI, at the expense of an unavoidable increased risk of major bleeding compared with single antiplatelet therapy. A personalised approach based on the patient clinical presentation (stable CAD or ACS), baseline ischaemic and bleeding risk profiles, and management strategy (conservative treatment, PCI or coronary artery bypass graft (CABG)) is currently advocated.2–5

STABLE CAD
Aspirin remains the cornerstone for secondary prevention of patients with stable CAD, irrespective of the management strategy. In a large meta-analysis including 16 secondary prevention trials and 17 000 high-risk patients, low-dose aspirin (75–150 mg/day) was associated with a 20% relative risk reduction in MACE (cardiovascular (CV) death or non-fatal myocardial infarction (MI)) (rate ratio 0.80, 95% CI 0.73 to 0.88), a 31% relative risk reduction in MI (RR 0.69, 95% CI 0.60 to 0.80) and a 22% relative risk reduction in ischaemic stroke (RR 0.78, 95% CI 0.61 to 0.99), at the expense of an increased risk of haemorrhagic stroke (RR 1.67, 95% CI 0.97 to 2.90) and major extracranial bleeding (RR 2.69, 95% CI 1.25 to 5.76).1 Aspirin marginally reduced CV mortality (RR 0.91, 95% CI 0.82 to 1.00, p=0.06), resulting in a 10% relative risk reduction in all-cause mortality (RR 0.90, 95% CI 0.82 to 0.99, p=0.02).1 At variance of the antiplatelet effects, the gastrointestinal side effects of aspirin increase at higher doses. The optimal risk:benefit ratio appears to be achieved with an aspirin dosage of 75–150 mg daily.2,6

The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial compared antiplatelet therapy with clopidogrel (75 mg daily) versus aspirin (325 mg daily) in 19 185 patients with atherosclerotic cardiovascular disease (ACVD) (recent ischaemic stroke, recent MI or symptomatic peripheral arterial disease (PAD)).7 Compared with aspirin, long-term administration of clopidogrel (median follow-up 2 years) was associated with significant risk reductions in the combined endpoint of CV death, MI or ischaemic stroke (5.32% per year vs 5.83% per year, relative risk reduction 8.7%, 95% CI 0.3 to 16.5, p=0.04) without significantly increased risk of severe intracranial (0.31% vs 0.43%, p=0.23) and gastrointestinal bleedings (0.49% vs 0.71%, p=0.05).7 Importantly, the superiority of clopidogrel over aspirin was mainly driven by a reduction of events in the PAD, but not MI, subgroup.7 Although potent P2Y₁₂ receptor inhibitors have shown superior efficacy than clopidogrel in patients with ACS, there is currently little evidence to support the use of prasugrel and ticagrelor in patients with stable CAD.

According to current guidelines, long-term low-dose aspirin is recommended in all patients with stable CAD (class I).2,6 Clopidogrel (75 mg daily) is indicated as an alternative in case of aspirin intolerance (class I).2 Alternatively, aspirin desensitisation may also be considered in patients with a compelling need for aspirin therapy.

Conservative treatment
Data supporting the benefits of long-term DAPT in unselected patients with stable CAD are limited. The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, Management and Avoidance (CHARISMA) trial randomly assigned 15 603 patients with documented ACVD (CAD, cerebrovascular disease or PAD) or multiple atherothrombotic risk factors to receive clopidogrel (75 mg daily) versus placebo in addition to low-dose aspirin (75–162 mg daily).8 Overall, rates of the primary composite endpoint (CV death, MI or stroke) were similar in the clopidogrel plus aspirin and aspirin alone groups after a median follow-up of 28 months (6.8% vs 7.3%, 95% CI 0.83 to 1.05, p=0.22), despite a marginally increased risk of severe bleeding among patients treated with DAPT (1.7% vs 1.3%, RR 1.25, 95% CI 0.97 to 1.61, p=0.09).8 In the subgroup of patients with multiple risk factors, the rates of the primary endpoint (6.6% vs 5.5%, RR 1.2, 95% CI 0.91 to 1.59, p=0.20) and CV death were higher in clopidogrel-treated patients (3.9% vs 2.2%, p=0.01). In the prespecified subgroup of patients with clinically evident ACVD (n=12 153), there was a marginally significant reduction in the primary ischaemic endpoint in the clopidogrel plus aspirin group (6.9% vs 7.9%, RR 0.88, 95% CI 0.77 to 0.998, p=0.046), whereas asymptomatic patients with multiple risk factors only (n=3284) assigned to clopidogrel plus aspirin experienced a 20% relative risk increase in the rate of primary ischaemic events (6.6% vs 5.5%, p=0.20) and a significant increase in rates of all-cause (5.4% vs 3.8%, p=0.04) and CV death (3.9% vs 2.2%, p=0.01), compared with those assigned to aspirin alone.8 In a posthoc subgroup analysis of 9478 patients with prior MI, ischaemic stroke or PAD, rates of the primary composite endpoint (7.3% vs 8.8%, HR 0.83, 95% CI 0.72 to 0.96, p=0.01) and hospitalisations for ischaemia (11.4% vs 13.2%, HR 0.86, 95% CI 0.76 to 0.96, p=0.008) were significantly lower in the clopidogrel plus aspirin arm than in the aspirin alone arm.9 In patients treated with DAPT, there was a significantly increased risk of moderate bleeding (2.0% vs 1.3%, HR 1.60, 95% CI 1.16 to 2.20, p=0.004) with no significant difference in rates of severe bleeding (1.7% vs 1.5%, HR 1.12, 95% CI 0.81 to 1.53, p=0.50).9

Routine DAPT is currently not recommended for patients with stable CAD without history of ACS, PCI or CABG within 12 months (class III).2,6 Results from the CHARISMA trial suggest the potential benefits of DAPT with aspirin and clopidogrel beyond aspirin alone in a subgroup of patients with stable CAD and at high risk of CV events (figure 1).

Percutaneous coronary intervention
The combination of aspirin and P2Y₁₂ receptor inhibitor therapy remains the mainstay of pharmacological treatment for patients undergoing PCI with bare metal stents (BMS) or drug-eluting stents (DES). Among patients undergoing PCI, DAPT with aspirin and a P2Y₁₂ receptor antagonist (ticlopidine) during 4–6 weeks significantly
reduced rates of MACE compared with combined aspirin and oral anticoagulation (OAC) therapy, or aspirin single antiplatelet therapy, and decreased major bleeding rates compared with combination of aspirin and OAC. However, prolonged DAPT duration increases the risk of major bleeding compared with aspirin alone, which has been strongly related to an increased risk of short- and long-term mortality. The Clopidogrel for the Reduction of Events during Observation (CREDO) trial randomly assigned 2116 patients scheduled for elective PCI or deemed at high likelihood of undergoing PCI to receive clopidogrel for up to 1 year (preceded by a 300 mg loading dose) or for 1 month (without loading dose), in addition to aspirin. At 1 year, long-term clopidogrel therapy was associated with a 27% relative risk reduction in the combined ischaemic endpoint (death, MI or stroke) (95% CI 3.9% to 44.4%, p=0.02; absolute reduction 3%) compared with a short clopidogrel regimen, at the expense of a marginally increased risk of major bleeding (8.8% vs 6.7%, p=0.07). While there is general consensus on 1-month DAPT duration after BMS implantation, the optimal duration of DAPT after DES implantation remains a matter of debate. Newer generation DES with thinner strut thickness, biocompatible or biodegradable polymer coatings, and reduced sirolimus-analogue antiproliferative drug doses have been developed to improve arterial healing and reduce the risk of late thrombotic adverse events, which may potentially mitigate the need for prolonged intense platelet inhibition after DES implantation.

The conflicting evidence concerning optimal DAPT duration after DES implantation is reflected in the contradictory results of 12 randomised controlled trials (RCT) performed to date to address this challenging and unsolved clinical issue. The inconsistent results may in part be explained by important differences in study designs, patient risk profiles, DAPT strategies, DES types implanted and study primary endpoints. Most of the trials have been characterised by slow enrolment, inclusion of low-risk patients and limited statistical power due to sample size estimates based on large event rates reductions or non-inferiority margins, coupled with lower than anticipated observed event rates. In addition, several study designs combined both efficacy and safety outcomes into a single primary endpoint, thus confusing the relative risks and benefits of individual ischaemic and bleeding outcomes.

Most of contemporary studies have compared either shorter (3–6 months) or longer (18–48 months) courses of DAPT versus 12-month DAPT duration, which has traditionally been considered as the recommended DAPT duration for most patients after DES implantation. Seven RCTs have consistently reported similar ischaemic outcomes but significantly reduced major bleeding rates with shorter 3- or 6-month compared with longer (≥12 months) DAPT durations after DES implantation (table 2). Conversely, with the exception of the DAPT study, four RCTs have consistently failed to demonstrate a reduction in ischaemic events with DAPT prolongation beyond 12 months (up to

---

**Figure 1** P2Y<sub>12</sub> receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. BMS, bare metal stent; CABG, coronary artery bypass graft surgery; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Table 2 Overview of major randomised controlled trials comparing short-term (3–6 months) versus long-term (≥12 months) DAPT duration after drug-eluting stent implantation

<table>
<thead>
<tr>
<th>Trial</th>
<th>Patients (N)</th>
<th>Clinical presentation</th>
<th>DAPT duration</th>
<th>Ischaemic endpoints</th>
<th>Bleeding endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXCELLENT</td>
<td>1443</td>
<td>SCAD 49% / ACS 51%</td>
<td>6 vs 12 months</td>
<td>TVF (CV death, MI or ischaemia-driven TVR): 4.8% vs 4.3%, HR 0.59, CI 0.70 to 0.86; MACE (death, MI, stroke or any revascularisation): 8.0% vs 8.5%, HR 0.94, CI 0.65 to 1.35, p=0.72; CV death: 0.3% vs 0.4%, HR 0.67, CI 0.11 to 0.99, p=0.66; MI: 1.8% vs 1.0%, HR 1.86, CI 0.74 to 4.67, p=0.19; ST: 0.9% vs 0.1%, HR 6.02, CI 0.72 to 29.46, p=0.10</td>
<td>TIMI major bleeding: 0.3% vs 0.6%, HR 0.50, CI 0.99 to 2.73, p=0.42</td>
</tr>
<tr>
<td>RESET</td>
<td>2117</td>
<td>SCAD 46% / ACS 54%</td>
<td>3 vs 12 months</td>
<td>MACE (all-cause death, MI or ST): 0.8% vs 1.3%, CV death: 0.2% vs 0.4%, MI: 0.2% vs 0.4%, definite/probable ST: 0.2% vs 0.3%, TIMI major bleeding: 0.2% vs 0.6%, p=0.16</td>
<td></td>
</tr>
<tr>
<td>PRODIGY</td>
<td>2013</td>
<td>SCAD 26% / ACS 74%</td>
<td>6 vs 24 months</td>
<td>MACE (all-cause death, MI or stroke): 10.0% vs 10.1%, HR 0.98, CI 0.74 to 1.29, CV death: 3.8% vs 3.7%, HR 1.03, CI 0.66 to 1.61, TIMI major bleeding: 3.5% vs 7.4%, HR 0.46, CI 0.31 to 0.69, p=0.00018</td>
<td></td>
</tr>
<tr>
<td>OPTIMIZE</td>
<td>3119</td>
<td>SCAD 68% / ACS 32%</td>
<td>3 vs 12 months</td>
<td>All-cause death: 2.8% vs 2.9%, HR 0.95, CI 0.63 to 1.45, p=0.82; CV death: 1.9% vs 2.1%, HR 0.90, CI 0.55 to 1.49, p=0.69; MI: 3.2% vs 2.7%, HR 1.17, CI 0.77 to 1.76, p=0.47; MACE (all-cause death, MI, emergent CABG or TLR): 3.15% vs 3.4%, HR 1.12, CI 0.87 to 1.45, p=0.36; definite/probable ST: 1.5% vs 1.3%, HR 1.15, CI 0.55 to 2.41, p=0.70; Major REPLACE-2 and severe or life-threatening GUSTO bleedings: 0.6% vs 0.9%, HR 0.71, CI 0.32 to 1.60, p=0.41, TIMI major bleeding: 0.6% vs 1.6%, HR 0.38, CI 0.15 to 0.97, p=0.041</td>
<td></td>
</tr>
<tr>
<td>SECURITY</td>
<td>1399</td>
<td>SCAD 62% / ACS 38%</td>
<td>6 vs 12 months</td>
<td>CV death: 0.7% vs 0.4%, MI: 2.3% vs 2.1%, p=0.747; definite/probable ST: 0.3% vs 0.4%, p=0.694</td>
<td>BARC type 3 or 5 at 12 months: 0.6% vs 1.1%, p=0.283</td>
</tr>
<tr>
<td>ITALIC</td>
<td>1894</td>
<td>SCAD 56% / ACS 44%</td>
<td>6 vs 24 months</td>
<td>All-cause death: 0.9% vs 0.8%, HR 1.14, CI 0.41 to 3.15, p=0.80; CV death: 0.5% vs 0.3%, HR 1.67, CI 0.39 to 6.97, p=0.48; MI: 0.7% vs 0.4%, HR 1.50, CI 0.42 to 5.32, p=0.53; TLR: 0.5% vs 0.2%, HR 2.49, CI 0.48 to 12.88, p=0.27; ST: 0.3% vs 0%</td>
<td>TIMI major bleeding: 0 vs 0.3%</td>
</tr>
<tr>
<td>ISAR-SAFE</td>
<td>4000</td>
<td>SCAD 60% / ACS 40%</td>
<td>6 vs 12 months</td>
<td>MACE (all-cause death, MI, definite/probable ST or stroke): 1.3% vs 1.5%, HR 0.87, CI 0.51 to 1.47, p=0.59; all-cause death: 0.4% vs 0.6%, HR 0.66, CI 0.27 to 1.63, p=0.37; MI: 0.7% vs 0.7%, HR 0.93, CI 0.42 to 1.97, p=0.85; definite/probable ST: 0.3% vs 0.2%, HR 1.25, CI 0.33 to 4.65, p=0.74</td>
<td>TIMI major bleeding: 0.2% vs 0.3%, HR 0.80, CI 0.21 to 2.98, p=0.74</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; BARC, Bleeding Academic Research Consortium; CABG, coronary artery bypass graft surgery; CV, cardiovascular; DAPT, dual antiplatelet therapy; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; MACCE, major adverse cardiac and cerebrovascular events; MACE, major adverse cardiovascular events; MI, myocardial infarction; REPLACE, Randomised Evaluation of PCI Linking Angiomax to Reduced Clinical Events; SCAD, stable coronary artery disease; ST, stent thrombosis; TIMI, thrombolysis in myocardial infarction; TLR, target lesion revascularisation; TVF, target vessel failure; TVR, target vessel revascularisation.

48 months), as compared with 12-month DAPT (table 3).

The Dual Antiplatelet Therapy (DAPT) study randomly assigned 9961 patients who underwent PCI with DES to continue thienopyridine therapy or to receive placebo for 18 months in addition to aspirin, after 12 months of DAPT combining aspirin and a thienopyridine (clopidogrel or prasugrel). Prolonged DAPT (30 months) after DES significantly reduced rates of stent thrombosis (ST) (0.4% vs 1.4%, HR 0.29, 95% CI 0.17 to 0.48, p<0.001), MACE (4.3% vs 5.9%, HR 0.71, 95% CI 0.59 to 0.85, p<0.001) and MI (2.1% vs 4.1%, HR 0.47, p<0.001), compared with 12-month DAPT duration. Continued thienopyridine therapy beyond 12 months was associated with marginally increased rates of all-cause mortality (2.0% vs 1.5%, HR 1.36, 95% CI 1.00 to 1.85, p=0.05) and a significantly increased risk of moderate or severe bleeding (2.5% vs 1.6%, p=0.001) compared with 12-month DAPT. Finally, there was an increased risk of ST and MI in both treatment groups during the 3 months.
period following discontinuation of thienopyridine treatment. In a posthoc analysis, extended DAPT duration was associated with significantly increased non-CV (0.9% vs 0.5%, p=0.01) but not CV death (1.0% vs 1.0%, p=0.97) rates throughout the randomised period. The rates of fatal bleeding (0.2% vs 0.1%, p=0.81) and death related to any prior bleeding (0.3% vs 0.2%, p=0.36) were similar between both treatment arms. Cancer-related deaths were more frequent in patients with extended DAPT treatment (0.6% vs 0.3%, p=0.02) and were rarely related to bleeding. However, rates of cancer occurring over the randomised period (2.0% vs 1.6%, p=0.12) or after exclusion of patients with cancer diagnosed before enrolment (0.4% vs 0.3%, p=0.16) were similar between both treatment groups. Overall, findings of the DAPT study suggest that continuation of DAPT beyond 1 year after DES implantation might be considered in selected patients at low ischaemic and bleeding risks to reduce the rates of ST and MI, at the expense of an increased risk of bleeding. The evidence derived from RCTs addressing different DAPT strategies after new generation DES implantation has been recently combined in several large meta-analyses. Shorter (3–6 months) DAPT courses have been associated with similar rates of MACE, all-cause death, CV death, MI, or repeat revascularisation, but with reduced rates of major bleeding compared with 12-month DAPT. Conversely, extended (18–48 months) DAPT durations have been associated with similar rates of MACE, all-cause death, CV death, MI, ST, and repeat revascularisation, and increased rates of major bleeding compared with shorter (6–12 months) DAPT durations. Although the DAPT study and two subsequent meta-analyses showed that extended DAPT duration beyond 1 year after DES may reduce the risk of MI and ST, it has been associated with increased mortality due to increased risk of non-CV mortality not offset by a reduction in CV mortality. However, a recent large meta-analysis including 69,644 patients undergoing stent implantation did not demonstrate an association between extended DAPT duration and all-cause, CV or non-CV mortality compared with aspirin alone or short DAPT duration (≤6 months). A personalised approach considering the balance between the ischaemic benefit and the bleeding risk

### Table 3
Overview of major randomised controlled trials comparing extended versus standard (12 months) dual antiplatelet therapy duration after drug-eluting stent implantation

<table>
<thead>
<tr>
<th>Trial</th>
<th>Patients (N)</th>
<th>Clinical presentation</th>
<th>DAPT duration</th>
<th>Ischaemic endpoints</th>
<th>Bleeding endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>REAL-LATE/</td>
<td>2701</td>
<td>SCAD 38% ACS 62%</td>
<td>36 vs 12 months</td>
<td>MACE (CV death, MI): 1.8% vs 1.2%, HR 1.65, 95% CI 0.80 to 3.36, p=0.17; all-cause death: 1.6% vs 1.4%, HR 1.52, 95% CI 0.75 to 3.50, p=0.24; MI: 0.8% vs 0.7%, HR 1.41, 95% CI 0.54 to 3.71, p=0.49; definite ST: 0.4% vs. 0.4%, HR 1.23, 95% CI 0.33 to 4.58, p=0.76</td>
<td>TIMI major bleeding: 0.2% vs 0.1%, HR 2.96, 95% CI 0.31 to 28.46, p=0.35</td>
</tr>
<tr>
<td>ZEST-LATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARCTIC-</td>
<td>1259</td>
<td>STEMI 0%</td>
<td>18–30 vs 12 months</td>
<td>MACE (death, MI, ST, stroke or urgent revascularisation): 4.0% vs 4.0%, HR 1.17, 95% CI 0.68 to 2.03, p=0.58; all-cause death: 1.0% vs 1.0%, HR 1.32, 95% CI 0.49 to 3.55, p=0.58; MI: 1.0% vs 1.0%, HR 1.04, 95% CI 0.41 to 2.62, p=0.94; ST or any urgent revascularisation: 1.0% vs 2.0%, HR 1.30, 95% CI 0.51 to 3.30, p=0.58</td>
<td>STEEPLE major bleeding: 1.0% vs &lt;0.5%, HR 0.15, 95% CI 0.02 to 1.20, p=0.07</td>
</tr>
<tr>
<td>Interruption</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collet et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DES LATE</td>
<td>5045</td>
<td>SCAD 39% ACS 61%</td>
<td>36 vs 12 months</td>
<td>MACE (cardiac death, MI or stroke): 2.6% vs 2.4%, HR 0.94, 95% CI 0.66 to 1.35, p=0.75; all-cause death: 2.0% vs 1.4%, HR 0.71, 95% CI 0.45 to 1.10, p=0.12; MI: 0.8% vs 1.2%, HR 1.43, 95% CI 0.80 to 2.58, p=0.23; definite ST: 0.3% vs 0.5%, HR 1.59, 95% CI 0.61 to 4.09, p=0.34</td>
<td>TIMI major bleeding: 1.4% vs 1.1%, HR 0.71, 95% CI 0.42 to 1.20, p=0.20</td>
</tr>
<tr>
<td>Lee et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAPT</td>
<td>9961</td>
<td>SCAD 57% ACS 43%</td>
<td>30 vs 12 months</td>
<td>MACCE: 4.3% vs 5.9%, HR 0.71, 95% CI 0.59 to 0.85, p&lt;0.001; MI: 2.1% vs 4.1%, HR 0.47, p&lt;0.001; ST: 0.4% vs 1.4%, HR 0.29, 95% CI 0.17 to 0.48, p&lt;0.001</td>
<td>GUSTO moderate or severe bleeding: 2.5% vs 1.6%, p=0.001; BARC type 2, 3 or 5: 5.6% vs 2.9%, p&lt;0.001</td>
</tr>
<tr>
<td>Mauri et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPTIDUAL</td>
<td>1385</td>
<td>SCAD 64% ACS 36%</td>
<td>48 vs 12 months</td>
<td>All-cause death: 2.3% vs 3.5%, HR 0.65, 95% CI 0.34 to 1.22, p=0.18; MI: 1.6% vs 2.3%, HR 0.67, 95% CI 0.31 to 1.44, p=0.31; definite/probable ST: 0.4% vs 0.1%, HR 2.97, 95% CI 0.31 to 28.53, p=0.35</td>
<td>ISTH major bleeding: 2.0% vs 2.0%, HR 0.98, 95% CI 0.47 to 2.05, p=0.95</td>
</tr>
<tr>
<td>Heft et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; CV, cardiovascular; DAPT, dual antiplatelet therapy; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; ISTH, International Society on Thrombosis and Haemostasis; MACCE, major adverse cardiac and cerebrovascular events; MACE, major adverse cardiovascular events; MI, myocardial infarction; SCAD, stable coronary artery disease; ST, stent thrombosis; STEEPL, Safety and Efficacy of Enoxaparin in PCI Patients, an International Randomised Evaluation; STEMI, STE-elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.
according to the patient’s clinical profile is currently advocated. For most of patients with stable CAD receiving contemporary DES, a short-term DAPT strategy (≤6 months) seems a reasonable approach, and may be considered the default therapy in the absence of an increased ischaemic risk. The clinical decision to extend DAPT duration beyond 1 year (18–48 months) after stent implantation requires a personalised evaluation to weigh up ischaemic benefits (lower risk of MI and ST) and risks (increased risk of major bleeding and non-CV death). However, further research is warranted to determine the optimal selection of patients who may derive benefit from extended DAPT duration after stent implantation.

Lifelong daily low-dose aspirin (75–150 mg) is currently recommended for secondary prevention of patients undergoing PCI for stable CAD (class I). Clodipogrel (75 mg daily) is indicated as an alternative therapy in case of aspirin intolerance (class I). Current European Society of Cardiology and American Heart Association/ American College of Cardiology guidelines recommend P2Y12 receptor inhibitor therapy with clopidogrel (75 mg daily) for a minimum duration of 1 month after BMS (class I) and 6 months after DES implantation (class I) for patients with stable CAD undergoing PCI. Due to the current lack of evidence in patients with stable CAD, the use of potent P2Y12 receptor antagonists, prasugrel or ticagrelor, is not recommended in low-risk elective PCI (class III), but may be considered in specific high-risk elective conditions, such as left main coronary artery PCI or patients at high risk of ST or with diabetes (class IIb). Premature discontinuation of P2Y12 receptor therapy after 3–6 months following DES implantation may be considered in patients deemed at high bleeding risk or who develop significant bleeding (class IIb). In patients at high ischaemic risk after BMS or DES implantation who have tolerated DAPT without bleeding and who are not at high bleeding risk, continuation of DAPT with clopidogrel for longer than 1 month in patients treated with BMS or longer than 6 months in patients treated with DES may be reasonable (class IIb) (figure 1).

The concept of DAPT will be challenged during the next years by several ongoing RCTs that will explore novel strategies using P2Y12 receptor inhibitors, clopidogrel (STOPDAPT-2 (NCT02619760), SMART-CHOICE (NCT02079194)) or ticagrelor (GLOBAL LEADERS (NCT01813435), TWILIGHT (NCT02270242)), as single antiplatelet therapy after a short-term (1 or 3 months) DAPT duration after new generation DES. GLOBAL LEADERS, the largest ongoing trial to date (16 001 patients enrolled), is a multicentre, open-label, randomised study investigating the superiority of a 23-month ticagrelor monotherapy (after a 1-month DAPT course combining aspirin and ticagrelor) over a conventional 12-month DAPT duration consisting of aspirin and clopidogrel (stable CAD) or ticagrelor (ACS) followed by an additional 12-month course of aspirin monotherapy with respect to the composite endpoint of all-cause mortality or non-fatal MI at 2 years in all-comers patients undergoing PCI with the uniform use of a newer generation DES. Similarly, TWILIGHT is a large-scale randomised, double-blind, placebo-controlled trial that will assess the efficacy and safety of ticagrelor monotherapy (after a 3-month DAPT course combining aspirin and ticagrelor) compared with standard 12-month DAPT with aspirin and ticagrelor in up to 9000 high-risk patients with stable CAD or ACS undergoing PCI with DES. The primary hypothesis of the trial is that ticagrelor monotherapy will be superior to DAPT with respect to rates of major bleeding, while maintaining non-inferiority for the risk of ischaemic events. These trials will provide novel insights with respect to the potential role of ticagrelor monotherapy as an alternative for long-term platelet inhibition in a broad population of patients undergoing PCI with DES.

Additionally, large all-comers trials are currently evaluating the safety and efficacy of an abbreviated 1-month DAPT duration compared with standard DAPT duration (6–12 months) in high bleeding risk patients undergoing PCI with newer generation DES (SENIOR (NCT02099617), MASTER DAPT (NCT03029390)). The highly anticipated results of these studies focused on patients who have been traditionally excluded from randomised trials on DAPT may provide robust randomised evidence to support a short DAPT regimen for high bleeding risk patients treated with newer generation DES in contemporary practice.

**CABG surgery**

Antiplatelet therapy with aspirin, preferably when initiated within 24 hours after CABG, has been shown to significantly improve early postoperative saphenous vein graft patency and reduce major adverse ischaemic events in patients undergoing surgical revascularisation. While aspirin administration remains a class I indication, the benefits of combined aspirin and clopidogrel therapy after CABG remain controversial. In a large meta-analysis including 25 728 patients after CABG, early saphenous vein graft occlusion (RR 0.59, 95% CI 0.43 to 0.82, p=0.02) and mortality rates (0.8% vs 1.9%, RR 0.38, 95% CI 0.26 to 0.57, p<0.0001) were significantly reduced among patients receiving aspirin and clopidogrel compared with those treated with aspirin alone, whereas rates of perioperative angina or MI were similar between the two treatment groups (RR 0.60, 95% CI 0.31 to 1.14, p=0.12). However, patients treated with DAPT showed a marginally increased risk of major bleeding, compared with those treated with aspirin alone (RR 1.17, 95% CI 1.00 to 1.37, p=0.05). In a pooled subgroup analysis of patients undergoing off-pump CABG, combined aspirin and clopidogrel therapy significantly reduced perioperative MI and saphenous vein graft occlusion rates by 68% and 55%, respectively. In another meta-analysis, antiplatelet monotherapy was associated with increased rates of early graft occlusion compared with DAPT (7.7% vs 5.0%, OR 1.59, 95% CI 1.16 to 2.17, p=0.005). These findings were mainly driven by significantly increased
ACUTE CORONARY SYNDROME

Antiplatelet therapy with aspirin remains the cornerstone of pharmacological therapy for patients with ACS, irrespective of the clinical setting (non-ST-elevation ACS (NSTEMI), or ST-elevation myocardial infarction (STEMI)) and the patient management strategy (conservative treatment, PCI or CABG). In a meta-analysis of 16 secondary prevention trials comparing long-term aspirin versus control therapy in 17,000 high-risk patients, aspirin significantly reduced MACE by 20% (absolute benefit 1%/year), non-fatal stroke by 19% and CV mortality by 9%. However, there is ongoing debate regarding the optimal maintenance dose of aspirin for secondary prevention of CV events in patients with ACS.

In the Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT-OASIS 7) trial including 25,086 patients with ACS, no significant difference was observed between high-dose (300–325 mg daily) and low-dose (75–100 mg daily) aspirin with regard to the composite endpoint of CV death, MI or stroke at 30 days (4.2% vs 4.4%, HR 0.97, 95% CI 0.86 to 1.09, p = 0.61), irrespective of the management strategy (conservative treatment or PCI). Low-dose aspirin was associated with significant lower rates of major gastrointestinal bleeding (0.2% vs 0.4%, p = 0.04), whereas high-dose aspirin showed no reduction in rates of the primary endpoint (4.1% vs 4.2%, HR 0.98, 95% CI 0.84 to 1.13, p = 0.76) or major bleeding (1.5% vs 1.3%, HR 1.18, 95% CI 0.92 to 1.53, p = 0.20) in the subgroup of patients undergoing PCI. Furthermore, a subanalysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial has recently suggested a reduced efficacy of ticagrelor versus clopidogrel in ACS patients treated with high aspirin doses, whereas ticagrelor appeared to be more effective than clopidogrel in decreasing CV events in patients on low-dose aspirin.

Although the exact mechanism underlying the potential interaction between ticagrelor and higher aspirin doses remains unclear, a proposed hypothesis is linked to the level of P2Y12 inhibition and the potential prothrombotic effects of high-dose aspirin through the suppression of prostacyclin. Overall, data regarding the use of aspirin for secondary prevention of CV events in patients with ACS demonstrate a general lack of benefit of high maintenance doses of aspirin owing to the absence of a dose–response relationship between increasing aspirin dose and improved efficacy, and a higher incidence of gastrointestinal bleeding with increasing aspirin doses. Compared with aspirin monotherapy, DAPT provides significant incremental reduction of CV events in patients with ACS and is considered the cornerstone of pharmacological treatment, irrespective of the management strategy.

Conservative treatment

In the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study comparing clopidogrel versus placebo in 12,562 patients with ACS, 64% of patients were...
treated conservatively and did not undergo revascularisation after randomisation. DAPT combining aspirin and clopidogrel for 3–12 months was associated with a significant reduction of the primary composite endpoint (CV death, non-fatal MI or stroke) compared with placebo (9.3% vs 11.4%, RR 0.80, 95% CI 0.72 to 0.90, p<0.001), at the expense of an increased risk of major bleeding in the clopidogrel group (3.7% vs 2.7%, RR 1.38, p=0.001). Nevertheless, rates of life-threatening bleeding (2.1% vs 1.8%, p=0.13), including fatal bleeding and haemorrhagic stroke, were similar between the two treatment groups.

The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial compared the efficacy and safety of prasugrel versus clopidogrel among 7243 patients <75 years with ACS receiving aspirin and undergoing conservative management. At a median follow-up of 17 months, no differences with regard to the primary composite endpoint (CV death, non-fatal MI or stroke) (13.9% vs 16%, HR 0.91, 95% CI 0.79 to 1.05, p=0.21) and severe or intracranial bleeding were observed between the two treatment groups. The prespecified analysis that was performed to account for multiple recurrent ischemic events suggested a lower risk in patients <75 years in the prasugrel group (HR 0.85, 95% CI 0.72 to 1.00, p=0.04). Conversely, in the subgroup analysis of the PLATO trial including 5216 patients (28% of the total population) managed conservatively, the clinical benefit of ticagrelor over clopidogrel was consistent with the results in the overall study population, with a 15% reduction in the composite primary endpoint (12.0% vs 14.3%, HR 0.85, 95% CI 0.73 to 1.00, p=0.04) and a 25% reduction in all-cause mortality (6.1% vs 8.2%, HR 0.75, 95% CI 0.61 to 0.93, p=0.01), despite a numerically higher incidence of total major bleeding (11.9% vs 10.3%, HR 1.17, 95% CI 0.98 to 1.39, p=0.08) and non-CABG-related major bleeding (4.0% vs 3.1%, HR 1.30, 95% CI 0.95 to 1.77, p=0.10) with ticagrelor than with clopidogrel. These results confirm the potential clinical superiority of an intense platelet inhibition with ticagrelor (but not prasugrel) over clopidogrel for selected patients with ACS undergoing conservative management.

Current guidelines recommend DAPT combining low-dose aspirin (75–100mg/day) and a P2Y12 receptor inhibitor (clopidogrel or ticagrelor) during 12 months for patients with ACS managed conservatively (class I). Although the use of ticagrelor over clopidogrel seems reasonable (class IIa), the administration of prasugrel is not recommended (class III). Long-term DAPT may be considered for selected patients who tolerated the DAPT regimen during the first 12 months without bleeding (class IIb) (figure 2).

Notwithstanding, contemporary randomised data on the optimal DAPT strategy for medically managed patients with ACS are scarce. Patients with ACS undergoing conservative management represent a large and highly heterogeneous population, and the generalisation of recommendations on the duration of DAPT for patients with ACS treated with PCI to this specific patient subgroup is questionable in view of the currently available evidence. Future research to determine the optimal antiplatelet regimen and duration in conservatively managed patients with ACS is therefore warranted.

**Percutaneous coronary intervention**

Intense P2Y12 receptor inhibition for patients with ACS undergoing PCI has been shown to improve clinical outcomes in RCTs comparing DAPT regimens with clopidogrel versus placebo, prasugrel versus clopidogrel, or ticagrelor versus clopidogrel.

In the subgroup of 2658 patients with NSTE-ACS undergoing PCI in the CURE study, pretreatment (median 6 days) followed by long-term therapy (median 10 days) with clopidogrel and aspirin was associated with a 31% reduction in the composite endpoint of CV death or MI at 30 days (8.8% vs 12.6%, RR 0.69, 95% CI 0.54 to 0.87, p=0.002) compared with aspirin and placebo. After PCI, most patients (>80%) in both arms (including in the aspirin alone arm) received open-label thienopyridine for about 4 weeks, after which study drug was restarted for a mean duration of 8 months. The Trial to Assess Improvement in Therapeutic Outcomes by Optimising Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 compared the clinical benefits of prasugrel versus clopidogrel for a duration of 6–15 months in combination with aspirin among 13,608 patients with moderate-to-high-risk ACS scheduled to undergo PCI. As compared with clopidogrel, prasugrel significantly reduced the risk of the primary composite endpoint (CV death, non-fatal MI or stroke) by 19% (9.9% vs 12.1%, HR 0.81, 95% CI 0.73 to 0.90), MI by 24% (7.3% vs 9.5%, HR 0.76, 95% CI 0.67 to 0.85), urgent target-vessel revascularisation (TVR) by 54% (2.5% vs 3.7%, HR 0.66, 95% CI 0.54 to 0.81) and ST by 52% (1.1% vs 2.4%, HR 0.48, 95% CI 0.36 to 0.64) at 12 months (p<0.001 for all), but increased the risk of non-CABG-related thrombolysis in myocardial infarction (TIMI) major bleeding (2.4% vs 1.8%, HR 1.32, 95% CI 1.03 to 1.6, p=0.03), including fatal bleeding. Overall mortality did not differ significantly between treatment groups (3.0% vs 3.2%, HR 0.95, 95% CI 0.78 to 1.16, p=0.64). In a posthoc subgroup analysis of patients with age ≥75 years, body weight <60kg or history of stroke or transient ischaemic attack (TIA), prasugrel was associated with increased clinical benefit with regard to the primary efficacy endpoint (16.1% vs 16.0%, HR 1.02, 95% CI 0.84 to 1.24, p=0.83) and increased risk of non-CABG-related TIMI major bleeding (4.3% vs 3.3%, HR 1.42, 95% CI 0.93 to 2.15, p=0.10) when compared with the overall cohort, resulting in less net clinical benefit or in clinical harm compared with clopidogrel.

In the PLATO trial, ticagrelor was compared with clopidogrel in addition to aspirin in 18,624 patients with ACS. At 12-month follow-up, ticagrelor significantly reduced the risk of the primary composite endpoint (CV...

death, non-fatal MI or stroke) by 16% (9.8% vs 11.7%, HR 0.84, 95% CI 0.77 to 0.92, p<0.001), MI by 16% (5.8% vs 6.9%, HR 0.84, 95% CI 0.75 to 0.95, p=0.005), all-cause (4.5% vs 5.9%, HR 0.78, 95% CI 0.69 to 0.89, p<0.001) and CV mortality (4.0% vs 5.1%, HR 0.79, 95% CI 0.69 to 0.91, p=0.001) by 22% and 21% respectively, compared with clopidogrel. Although no significant difference was observed in the overall incidence of major bleeding (11.6% vs 11.2%, HR 1.04, 95% CI 0.95 to 1.13, p=0.43), ticagrelor was associated with significantly increased rates of non-CABG-related major bleeding (4.5% vs 3.8%, HR 1.19, 95% CI 1.02 to 1.38, p=0.03). The significant differences in TRITON-TIMI 38 and PLATO study designs preclude any interpretation from indirect comparisons between the two potent oral P2Y12 receptor inhibitors. Recently, the efficacy and safety of ticagrelor versus prasugrel in patients with STEMI treated with primary PCI were compared in the Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction (PRAGUE-18) study, which was prematurely terminated for futility after inclusion of 1230 patients. The occurrence of the primary composite endpoint (death, MI, TVR, stroke, serious bleeding requiring transfusion or prolonging hospitalisation) at 7 days was not significantly different between patients receiving prasugrel and ticagrelor (4.0% vs 4.1%, OR 0.98, 95% CI 0.55 to 1.73, p=0.94) and no significant difference was found in any of the components of the primary composite endpoint. The occurrence of the secondary composite endpoint (CV death, non-fatal MI or stroke) within 30 days was similar among patients treated with prasugrel or ticagrelor (2.7% vs 2.5%, OR 1.06, 95% CI 0.53 to 2.15, p=0.86). Despite being small and underpowered, this first head-to-head comparison of prasugrel and ticagrelor in patients with STEMI undergoing primary PCI does not support the superiority of one of the potent P2Y12 receptor inhibitors for the prevention of ischaemic and bleeding events.

Current guidelines recommend DAPT combining long-term, low-dose aspirin (75–100 mg/day) and a P2Y12 receptor inhibitor therapy (clopidogrel, ticagrelor or prasugrel) for at least 12 months in patients with ACS undergoing PCI, irrespective of the stent type (BMS or DES) (class I). The use of potent P2Y12 receptor antagonists (ticagrelor for patients at moderate-to-high risk of ischaemic events, including patients who were pretreated with clopidogrel, or prasugrel) should be preferred over clopidogrel (patients who cannot receive ticagrelor or prasugrel, or who require long-term OAC therapy). Prasugrel is not recommended for patients in whom coronary anatomy is not known (class III), or with history of
stroke or TIA (class III).\textsuperscript{5,6} In patients at high bleeding risk or who develop significant bleeding, premature discontinuation of DAPT after 3\textsuperscript{5} or 6\textsuperscript{5-6} months may be reasonable (class IIb). In patients with low bleeding risk who have tolerated DAPT during 12 months without bleeding complications, long-term continuation of DAPT may be considered (class IIb).\textsuperscript{6} (figure 2).

Nevertheless, current recommendations on the optimal duration of DAPT in patients with ACS are not based on contemporary randomised evidence.\textsuperscript{50-52} Notably, the median duration of DAPT in the pivotal trials evaluating the efficacy and safety of the combination of aspirin and a P2Y\textsubscript{12} receptor inhibitor in patients with ACS was 9–12 months with clopidogrel,\textsuperscript{15} 14.5 months with prasugrel\textsuperscript{54} and only 9.2 months with ticagrelor.\textsuperscript{52} Furthermore, no randomised evidence focused on patients with ACS is currently available comparing shorter versus standard or extended DAPT durations with respect to clinical outcomes in contemporary practice, whereas randomised data from prespecified ACS subgroup analyses of recent trials including patients treated with newer generation DES have consistently shown that shorter durations of DAPT (3–6 months) were non-inferior to 12\textsuperscript{18} 19 22-24 54 55 or 24\textsuperscript{20} months with respect to composite endpoints of CV events or CV events plus major bleeding. The optimal duration of DAPT in patients with ACS treated with DES remains therefore still under debate. Large-scale randomised trials (REDUCE (NCT02118870), SMART-DATE (NCT01701453)) are currently investigating the efficacy and safety of a short-term DAPT strategy (3 months and 6 months, respectively) compared with the recommended 12-month DAPT duration in patients with ACS undergoing PCI with newer generation DES and should provide novel insights into this important clinical dilemma during the next years.

**CABG surgery**

There is little evidence concerning the benefits and risks of a combined aspirin and P2Y\textsubscript{12} receptor inhibitor therapy for patients with ACS undergoing surgical revascularisation owing to major concerns concerning the risk of perioperative major bleeding complications with intense antiplatelet inhibition. In the subgroup of patients undergoing CABG in the CURE study (n=2072, 16.5\%), clopidogrel in addition to aspirin was associated with a 11% relative risk reduction in rates of the primary composite endpoint (CV death, MI or stroke) compared with placebo (14.5% vs 16.2\%, RR 0.89, 95% CI 0.71 to 1.11), despite marginally increased rates of life-threatening bleeding events in the clopidogrel arm (5.6\% vs 4.2\%, RR 1.30, 95% CI 0.91 to 1.95).\textsuperscript{35} These findings were consistent with the treatment effect observed in the overall study population and suggest that the benefits of a DAPT with clopidogrel in patients with ACS may outweigh the risks among patients who undergo CABG during the initial hospitalisation. Data concerning more potent P2Y\textsubscript{12} receptor antagonists, prasugrel or ticagrelor, are currently limited to posthoc analyses of RCTs. In a subgroup analysis of patients with ACS who underwent isolated CABG in the TRITON-TIMI 38 study (n=346), all-cause mortality within 30 days was significantly reduced with prasugrel compared with clopidogrel (2.3% vs 8.7\%, OR 0.26, p=0.025), despite significantly higher mean chest tube blood loss at 12 hours and platelet transfusion rates, and marginally increased rates of red blood cell transfusion and surgical re-exploration for bleeding in the prasugrel arm.\textsuperscript{56} In the subgroup of patients with ACS who underwent CABG within 7 days after the last study drug intake in the PLATO trial (n=1261, 6.8\%), ticagrelor was associated with significantly reduced rates of total mortality (4.7% vs 9.7\%, HR 0.49, 95% CI 0.32 to 0.77, p<0.01) and CV death (4.1% vs 7.9\%, HR 0.52, 95% CI 0.32 to 0.85, p<0.01) compared with clopidogrel.\textsuperscript{57} The relative risk reduction of the primary composite endpoint (CV death, MI or stroke) at 12 months in the CABG subgroup (10.6\% with ticagrelor vs 13.1\% with clopidogrel, HR 0.84, 95% CI 0.60 to 1.16, p=0.29) was consistent with the results of the overall trial, without significant difference in CABG-related major bleeding rates between treatment arms.\textsuperscript{57}

For patients with ACS (NSTE-ACS or STEMI) treated with DAPT and undergoing surgical revascularisation, current guidelines recommend to resume the P2Y\textsubscript{12} receptor inhibitor therapy after CABG to complete the 12-month DAPT duration after ACS (class I).\textsuperscript{3,5,6} (figure 2). Due to the lack of randomised evidence, the appropriate antiplatelet regimen after CABG remains an area of controversy, and large, multicentre, randomised clinical trials are needed to definitively investigate the role of DAPT in patients with ACS after CABG.

**SPECIAL POPULATIONS AND CONDITIONS**

**High-risk patients with prior acute MI**

Current guidelines recommend DAPT with a P2Y\textsubscript{12} receptor antagonist for 1 year after acute MI.\textsuperscript{3,5,6} However, patients with prior MI remain at increased long-term risk for ischaemic events (CV death, MI or stroke) during the subsequent years.\textsuperscript{58} The potential benefit of extended duration of DAPT beyond 1 year for the long-term secondary prevention of CV events after MI remains a matter of debate. In a posthoc analysis of the CHARISMA trial, high-risk patients with documented prior MI, ischaemic stroke or symptomatic PAD (n=9478) were shown to derive significant benefit with regard to subsequent ischaemic events from long-term intensification of antiplatelet therapy beyond aspirin alone. After a median follow-up duration of 27.6 months, rates of the primary composite endpoint (CV death, MI or stroke) were significantly lower in the DAPT arm combining aspirin and clopidogrel than in the aspirin arm (7.3\% vs 8.8\%, HR 0.83, 95% CI 0.72 to 0.96, p=0.01) without significant differences in severe bleeding rates (1.7% vs 1.5\%, HR 1.12, 95% CI 0.81 to 1.53, p=0.50). However, the incidence of moderate bleeding was significantly increased in the aspirin plus
clopidogrel group (2.0% vs 1.3%, HR 1.60, 95% CI 1.16 to 2.20, p=0.004).

The Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared with Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial is the largest RCT to date evaluating the benefits of long-term DAPT for secondary prevention in high-risk patients with prior MI. PEGASUS-TIMI 54 randomised 21 162 patients with stable CAD, prior MI 1–3 years before inclusion and at high CR risk (21 high risk criteria: age ≥65 years, diabetes, second MI, multivessel CAD or chronic kidney disease) to aspirin monotherapy (75–150 mg daily) versus DAPT combining aspirin and ticagrelor (60 or 90 mg twice daily). After a median follow-up of 33 months, the two ticagrelor doses in addition to aspirin were associated with significantly reduced rates of the primary composite efficacy endpoint (CV death, MI or stroke) as compared with placebo (7.85%, 7.77% and 9.04% at 3 years in ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily and placebo groups, respectively; HR ticagrelor 90 mg vs placebo 0.85, 95% CI 0.75 to 0.96, p=0.008; HR ticagrelor 60 mg vs placebo 0.84, 95% CI 0.74 to 0.95, p=0.004). Rates of TIMI major bleeding were higher with ticagrelor than with placebo (2.6%, 2.3% and 1.06% at 3 years, respectively; HR ticagrelor 90 mg vs placebo 2.69, 95% CI 1.96 to 3.70, p<0.001; HR ticagrelor 60 mg vs placebo 2.32, 95% CI 1.60 to 3.21, p<0.001), whereas rates of fatal bleeding or non-fatal intracranial haemorrhage did not differ significantly between either ticagrelor dose group and placebo (0.63%, 0.71% and 0.6% at 3 years, respectively). These findings were recently confirmed in a large meta-analysis including 33 435 high-risk patients with history of MI. After a mean follow-up of 31 months, prolonged DAPT was associated with significantly reduced rates of MACE (6.4 vs 7.5%, RR 0.78, 95% CI 0.67 to 0.90, p=0.001), CV death (2.3 vs 2.6%, RR 0.85, 95% CI 0.74 to 0.98, p=0.03), MI (RR 0.70, 95% CI 0.55 to 0.88, p=0.003), stroke (RR 0.81, 95% CI 0.68 to 0.97, p=0.02) and ST (RR 0.50, 95% CI 0.28 to 0.89, p=0.02), when compared with aspirin alone, with no significant increase in non-CV (RR 1.03, 95% CI 0.86 to 1.23, p=0.76) and all-cause mortality (RR 0.92, 95% CI 0.83 to 1.03, p=0.13). Extended DAPT was associated with increased risk of major bleeding (1.85 vs 1.09%, RR 1.73, 95% CI 1.19 to 2.50, p=0.004) but not fatal bleeding (0.14 vs 0.17%, RR 0.91, 95% CI 0.53 to 1.58, p=0.75).

In a posthoc analysis of PEGASUS-TIMI 54, the net clinical benefit of ticagrelor for long-term secondary prevention in high-risk patients with prior MI seemed more pronounced in patients continuing on, or restarting after only a brief interruption, P2Y<sub>12</sub> inhibition, when compared with patients with stable CAD (no MACE for ≥2 years after MI) and off P2Y<sub>12</sub> inhibitor therapy for >1 year, irrespective of time from MI. For clinicians considering a strategy of prolonged DAPT in high-risk patients post-MI, these data suggest greater benefit in the continuation of P2Y<sub>12</sub> inhibitor therapy without interruption after MI, rather than reinitiating such therapy in patients who have remained stable for an extended period.

In patients at high ischaemic risk after acute MI, continuation of P2Y<sub>12</sub> receptor inhibitor therapy (preferably with ticagrelor 60 mg twice daily) in addition to low-dose aspirin beyond 1 year may be considered after careful assessment of the patient ischaemic and bleeding risks (class IIIb) (figures 1 and 2). However, future studies and development of practical clinical tools are warranted to clarify further the optimal selection of post-MI patients most likely to derive clinical benefit from long-term DAPT after MI.

**Patients requiring long-term oral anticoagulant therapy**
Approximately 6–8% of patients undergoing PCI have a concomitant indication for long-term OAC with a vitamin K antagonist (VKA) or a non-VKA oral anticoagulant (NOAC) for conditions such as atrial fibrillation (AF), left ventricular thrombus, mechanical valve prosthesis or venous thromboembolism. Current evidence to guide the management of patients undergoing PCI and requiring long-term OAC practice remains limited. Compared with VKA alone, dual therapy (clopidogrel and VKA) and triple therapy (VKA and DAPT with a P2Y<sub>12</sub> receptor inhibitor) in patients with AF following MI or PCI have been shown to increase the risk of major fatal and non-fatal bleeding. Omission of aspirin while maintaining P2Y<sub>12</sub> receptor antagonist has been evaluated in the What is the Optimal antiplatElet and anticoagulant therapy in patients with OAC and coronary StenTing (WOEST) trial, an open-label, multicentre RCT including 573 patients receiving oral anticoagulant therapy (AF or flutter 69%) and candidates for PCI (DES 65%) for stable CAD or ACS (25%–30%), who were assigned to clopidogrel alone (dual therapy) or clopidogrel plus aspirin (triple therapy) for 1 month after BMS and 1 year after DES. The rates of the primary safety outcome (any bleeding episode) at 1 year were significantly reduced in the dual therapy arm, as compared with the triple therapy arm (19.4% vs 44.4%, HR 0.36, 95% CI 0.26 to 0.50, p=0.0001), mainly driven by significant reductions in non-intracranial bleedings. Despite being small and underpowered for hard clinical outcomes, the trial showed a significant reduction of the secondary composite ischaemic endpoint (death, MI, stroke, TVR or ST) in the dual therapy group (11.1% vs 17.6%, HR 0.60, 95% CI 0.38 to 0.94, p=0.025) as compared with patients on triple therapy. These data suggest the potential superiority of dual antithrombotic therapy with regard to occurrence of major bleedings compared with triple therapy among patients undergoing PCI and who are candidates for long-term OAC, without evidence of increased risk of thrombotic events by omission of aspirin.

The Intracoronary Stenting and Antithrombotic Regimen-Testing of a 6 Week Versus a 6 Month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-Eliciting Stenting (ISAR-TRIPLE) trial enrolled 614 patients receiving OAC.
and who underwent DES implantation to 6-week versus 6-month clopidogrel therapy in addition to aspirin. The rates of the primary composite endpoint (death, MI, definite ST, stroke or TIMI major bleeding) at 9 months were similar between the two treatment groups (9.8% vs 8.8%, HR 1.14, 95% CI 0.68 to 1.91, p=0.63). Despite low event rates, there were no significant differences for the secondary combined ischaemic endpoint (CV death, MI, definite ST and ischaemic stroke) (4.0% vs 4.3%, HR 0.93, 95% CI 0.43 to 2.05, p=0.87) or the secondary bleeding endpoint of TIMI major bleeding (5.3% vs 4.0%, HR 1.35, 95% CI 0.64 to 2.84, p=0.44).

Recently, the Open-Label, Randomised, Controlled, Multi-center Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) trial randomly assigned 2124 patients with non-valvular AF who underwent PCI to receive in a 1:1:1 ratio low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months (group 1), very-low-dose rivaroxaban (2.5 mg once daily) plus a P2Y12 inhibitor for 12 months (group 2), or vitamin K antagonist for 12 months (group 3). The primary composite endpoint of death, MI, definite ST and ischaemic stroke at 12 months was 3.1% in group 1, 3.2% in group 2, and 5.1% in group 3 (HR 1.72, 95% CI 0.99 to 2.99, p=0.05).

**Figure 3** Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome; NOAC: non-vitamin K antagonist oral anticoagulant; PCI: percutaneous coronary intervention; OAC: oral anticoagulation; SCAD: stable coronary artery disease; VKA: vitamin K antagonist. 

- **a** Dual therapy with oral anticoagulation and single antiplatelet therapy (aspirin or clopidogrel) may be considered in selected patients at low ischaemic risk.
- **b** Dual antiplatelet therapy (aspirin and clopidogrel) may be considered.
- **c** Dual therapy with oral anticoagulation and aspirin (as an alternative to clopidogrel) may be considered.
- **d** Dual therapy with oral anticoagulation and single antiplatelet therapy (aspirin or clopidogrel) up to 12 months may be considered in selected patients, particularly for patients managed medically or undergoing CABG.
- **e** Dual therapy with oral anticoagulation and a single antiplatelet agent (aspirin or clopidogrel) may be considered in patients at very high risk of coronary events.
- **f** Dual therapy with oral anticoagulation and clopidogrel may be considered in selected patients at low ischaemic risk.
- **g** Triple therapy with oral anticoagulation and dual antiplatelet therapy (aspirin and clopidogrel) may be considered up to 12 months in very selected patients at high risk of ischaemic events: prior stent thrombosis on adequate antiplatelet therapy, left main coronary artery or last remaining patent coronary artery stenting, multiple stenting in proximal coronary artery segments, two stents bifurcation treatment, or diffuse multivessel coronary artery disease, particularly in patients with diabetes mellitus.
- **h** Choice and dose of oral anticoagulants used in combination with antiplatelet therapy: Vitamin K antagonist (International Normalised Ratio 2-2.5); Dabigatran 110 mg once daily; Rivaroxaban 15 mg once daily; Apixaban 2.5 mg twice daily; Edoxaban 30 mg (or 15 mg) once daily.


13
twice daily) plus DAPT for 1, 6 or 12 months (group 2), or standard therapy with a dose-adjusted VKA plus DAPT for 1, 6 or 12 months (group 3). At 12 months, rates of the primary safety endpoint (clinically significant bleeding) were significantly lower in the two groups receiving rivaroxaban compared with the standard therapy group (16.8% in group 1, 18.0% in group 2 and 26.7% in group 3; HR for group 1 vs group 3 0.59, 95% CI 0.47 to 0.76, \( p<0.001 \); HR for group 2 vs group 3 0.63, 95% CI 0.50 to 0.80, \( p<0.001 \)). The secondary combined ischaemic endpoint (CV death, MI or stroke) occurred similarly in the three treatment groups (6.5% in group 1, 5.6% in group 2 and 6.0% in group 3; p values for all comparisons non-significant). The secondary combined ischaemic endpoint (CV death, MI or stroke) occurred similarly in the three treatment groups (6.5% in group 1, 5.6% in group 2 and 6.0% in group 3; p values for all comparisons non-significant). Notwithstanding, the absence of a ‘WOEST-like’ control arm and the broad CIs observed for individual components of the secondary endpoint may preclude any definitive conclusions concerning the risk of thrombotic events of a low-dose or very low-dose rivaroxaban strategy combined with P2Y\(_{12}\) inhibitor monotherapy or DAPT. Future randomised studies adequately powered for efficacy endpoints are needed to confirm the potential superiority of an antithrombotic strategy combining a low-dose NOAC and a P2Y\(_{12}\) receptor inhibitor monotherapy over triple antithrombotic therapy for patients with non-valvular AF undergoing PCI.

Until further data from large RCTs become available, current consensus statements recommend an individualised approach and advocate to limit as possible the duration of triple therapy, depending on the clinical setting (stable CAD vs ACS), the thromboembolic risk (CHA\(_{DS}_{2}\)-VASc score) and the bleeding risk (eg, HAS-BLED score) (figure 3). The indication for OAC should be carefully reassessed in patients requiring DAPT and anticoagulant therapy continued only if a compelling indication is

---

**Figure 4** P2Y\(_{12}\) receptor inhibitor therapy for secondary prevention of patients with coronary artery disease. BMS, bare metal stent; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MI, myocardial infarction; PCI, percutaneous coronary intervention.
present. The dose intensity of OAC should be carefully monitored with a target INR of 2.0–2.5 in patients treated with VKA (except patients with mitral mechanical prosthetic valves) and time in therapeutic window with VKA (except patients with mitral mechanical pros-
thetic valves) and time in therapeutic window

CONCLUSION

Despite a large body of randomized evidence, the optimal regimen and duration of DAPT for secondary prevention of patients with CAD remains a matter of intense debate. Future studies are needed to better identify patients who may derive benefit from either shortened or prolonged DAPT durations to improve outcomes while minimising bleeding risks. Until more evidence becomes available, the optimal DAPT regimen and duration for patients with CAD requires a tailored approach based on the patient clinical presentation, baseline risk profile and management strategy (figure 4). Several ongoing large-scale randomised trials are currently investigating novel antiplatelet strategies and will contribute to refining the optimal regimen and duration of DAPT for secondary prevention of patients with CAD in the near future.

Acknowledgements

The authors warmly thank Christian Chervet for his help for the figure’s layout.

Contributors

Dr JFI (corresponding author) attests that the coauthors have participated in the redaction of this manuscript.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

There are no additional data available for this paper.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


Dual antiplatelet therapy for secondary prevention of coronary artery disease

Sophie Degrauwe, Thomas Pilgrim, Adel Aminian, Stephane Noble, Pascal Meier and Juan F Iglesias

Open Heart 2017 4:
doi: 10.1136/openhrt-2017-000651

Updated information and services can be found at:
http://openheart.bmj.com/content/4/2/e000651

These include:

References
This article cites 66 articles, 26 of which you can access for free at:
http://openheart.bmj.com/content/4/2/e000651#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/